Evaluating and reporting persons under investigation (PUI) by unknown
Coronavirus Disease 2019 (COVID-19)
Evaluating and Reporting Persons Under
Investigation (PUI)
Summary of Recent Changes
Revisions were made on February 27, 2020, to reflect the following:
Information updated in the “Criteria to Guide Evaluation of PUI for COVID-19” section.
Updated February 27, 2020
Limited information is available to characterize the spectrum of clinical illness associated with coronavirus disease 2019
(COVID-19). No vaccine or specific treatment for COVID-19 is available; care is supportive.
The CDC clinical criteria for a COVID-19 person under investigation (PUI) have been developed based on what is known
about MERS-CoV and SARS-CoV and are subject to change as additional information becomes available.
Healthcare providers should obtain a detailed travel history for patients being evaluated with fever and acute respiratory
illness. CDC guidance for evaluating and reporting a PUI for MERS-CoV remains unchanged.
!
Contact your local or state health department
Healthcare providers should immediately notify their local  or state  health department in the event
of a PUI for COVID-19.
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Criteria to Guide Evaluation of PUI for COVID-19
Local health departments, in consultation with clinicians, should determine whether a patient is a PUI for COVID-2019.
The CDC clinical criteria for COVID-19 PUIs have been developed based on available information about this novel virus, as
well as what is known about Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)
These criteria are subject to change as additional information becomes available.
Clinical Features & Epidemiologic Risk
Fever  or signs/symptoms of lower respiratory illness
(e.g. cough or shortness of breath)
AND Any person, including healthcare workers , who
has had close contact  with a laboratory-
confirmed  COVID-19 patient within 14 days of
symptom onset
Fever  and signs/symptoms of a lower respiratory illness
(e.g., cough or shortness of breath) requiring
hospitalization
AND A history of travel from affected geographic
areas  (see below) within 14 days of symptom
onset
Fever  with severe acute lower respiratory illness (e.g.,
pneumonia, ARDS) requiring hospitalization and without
alternative explanatory diagnosis (e.g., influenza)
AND No source of exposure has been identified
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Affected Geographic Areas with Widespread or Sustained Community Transmission
Last updated February 26, 2020
China
Iran
Italy
Japan
South Korea
The criteria are intended to serve as guidance for evaluation. In consultation with public health departments, patients
should be evaluated on a case-by-case basis to determine the need for testing. Testing may be considered for deceased
persons who would otherwise meet the PUI criteria.
Recommendations for Reporting, Testing, and Specimen
Collection
Updated February 3, 2020
Healthcare providers should immediately notify both infection control personnel at their healthcare facility and their
local or state health department in the event of a PUI for COVID-19. State health departments that have identified a PUI
should immediately contact CDC’s Emergency Operations Center (EOC) at 770-488-7100 and complete a COVID-19 PUI
case investigation form available below.
Download fillable PDF form
Download Microsoft Word form
CDC’s EOC will assist local/state health departments to collect, store, and ship specimens appropriately to CDC, including
during afterhours or on weekends/holidays.
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Testing for other respiratory pathogens should not delay specimen shipping to CDC. If a PUI tests positive for another
respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be
considered a PUI. This may evolve as more information becomes available on possible COVID-19 co-infections.
For biosafety reasons, it is not recommended to perform virus isolation in cell culture or initial
characterization of viral agents recovered in cultures of specimens from a PUI for COVID-19.
To increase the likelihood of detecting COVID-19, CDC recommends collecting and testing multiple clinical specimens
from different sites, including two specimen types—lower respiratory and upper respiratory. Additional specimen types
(e.g., stool, urine) may be collected and stored. Specimens should be collected as soon as possible once a PUI is identified
regardless of time of symptom onset. Additional guidance for collection, handling, and testing of clinical specimens is
available.
Interim Healthcare Infection Prevention and Control
Recommendations for Persons Under Investigation for COVID-19
Interim Infection Prevention and Control Recommendations for Patients with Confirmed COVID-19 or Persons Under
Investigation for COVID-19 in Healthcare Settings
Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings
CDC Health Alert Network Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV)
Footnotes
Fever may be subjective or confirmed
For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19
without laboratory confirmation. Because of their often extensive and close contact with vulnerable patients in
healthcare settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be evaluated among potentially
exposed healthcare personnel. Additional information is available in CDC’s Interim U.S. Guidance for Risk Assessment and
Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with
Coronavirus Disease 2019 (COVID-19).
Close contact is defined as—
a) being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time; close contact can
occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case
– or –
b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on)
If such contact occurs while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves,
NIOSH-certified disposable N95 respirator, eye protection), criteria for PUI consideration are met.
Additional information is available in CDC’s updated Interim Infection Prevention and Control Recommendations for
Patients with Confirmed COVID-19 or Persons Under Investigation for COVID-19 in Healthcare Settings.
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Data to inform the definition of close contact are limited. Considerations when assessing close contact include the
duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person
with COVID-19 (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient). Special
consideration should be given to healthcare personnel exposed in healthcare settings as described in CDC’s Interim
U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in
a Healthcare Setting to Patients with COVID-19.
Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for COVID-19
patients in other countries.
Affected areas are defined as geographic regions where sustained community transmission has been identified.
Relevant affected areas will be defined as a country with at least a CDC Level 2 Travel Health Notice. See all COVID-19
Travel Health Notices.
Category includes single or clusters of patients with severe acute lower respiratory illness (e.g., pneumonia, ARDS) of
unknown etiology in which COVID-19 is being considered.
Additional Resources:
State health department after-hours contact list
Directory of Local Health Departments
World Health Organization (WHO) Coronavirus
WHO guidance on clinical management of severe acute respiratory infection when COVID-19 is suspected
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